Last reviewed · How we verify
mesenchymal stem cell-derived exosomes — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
mesenchymal stem cell-derived exosomes (mesenchymal stem cell-derived exosomes) — First Affiliated Hospital of Guangxi Medical University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| mesenchymal stem cell-derived exosomes TARGET | mesenchymal stem cell-derived exosomes | First Affiliated Hospital of Guangxi Medical University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- mesenchymal stem cell-derived exosomes CI watch — RSS
- mesenchymal stem cell-derived exosomes CI watch — Atom
- mesenchymal stem cell-derived exosomes CI watch — JSON
- mesenchymal stem cell-derived exosomes alone — RSS
Cite this brief
Drug Landscape (2026). mesenchymal stem cell-derived exosomes — Competitive Intelligence Brief. https://druglandscape.com/ci/mesenchymal-stem-cell-derived-exosomes. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing